"Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockad" by Tessa Knox, Eva Sahakian et al.
 

Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells.

Document Type

Journal Article

Publication Date

4-16-2019

Journal

Sci Rep

Volume

9

Issue

1

DOI

10.1038/s41598-019-42237-3

Comments

This is an open access PubMed Central article.

Peer Reviewed

1

Open Access

1

Find in your library

Plum Print visual indicator of research metrics
PlumX Metrics
  • Citations
    • Citation Indexes: 131
    • Patent Family Citations: 1
  • Usage
    • Abstract Views: 43
  • Captures
    • Readers: 76
see details

Share

COinS